Type 1 Diabetes TrialNet ANZ

22/04/2020

COVID-19 is not stopping the TrialNet mission. We have modified a few things, but type 1 diabetes research in TrialNet continues and you can still help...

04/09/2019

Dr Michael Haller is in AUS!

Type 1 Diabetes TrialNet researcher Dr Michael Haller (pictured centre) visited the Australia/New Zealand TrialNet Coordintating Centre at the The Royal Melbourne Hospital/Walter and Eliza Hall Institute this morning to share the results of the ATG-GCSF study in newly diagnosed type 1 diabetes.

The Two-year findings of this study confirmed continuation of the positive effects reported 1 year after the start of treatment:

* Low-dose Thymoglobulin preserved beta cell function and improved insulin production.
* Haemoglobin A1c (HbA1c) levels were significantly lower (indicating better long-term blood glucose control) in people treated with low-dose Thymoglobulin alone and those treated with low-dose Thymoglobulin combined with Neulasta,when compared to placebo.

Read the published findings at https://diabetes.diabetesjournals.org/content/early/2019/03/21/db19-0057

05/10/2018

Fun fact 🧠✨

Jamie Cripps is an AFL Premiership player with T1D!

He has to check his blood sugar at quarter-time, half-time, three-quarter time and full-time every match, but that didn't stop him from scoring a goal in the Grand Final (and 38 for the season) for the West Coast Eagles.

Read more about his inspirational story below 🏈👇

In 2010, Jamie Cripps was lying in a hospital bed with a secret he didn't want AFL clubs to find out about. Cripps was an 18-year-old rising star who looked d...

10/09/2018

Participant Spotlight ✨

Check out Sophie at the Royal Melbourne Hospital and the Walter and Eliza Hall Institute before making the most of her time in Melbourne at the Melbourne Zoo!

Every month, young Sophie travels from Newcastle with her parents to participate in one of our Type 1 Diabetes studies.

After joining TrialNet, we found Sophie to be eligible for our Type 1 prevention study Abatacept. Now she's helping us find an even brighter future for those living with T1D 😇

We hope you had fun at the Zoo, Sophie! 🐒🦁🐘🦍

If you have a family member with Type 1, TrialNet can help you understand your own risk while working towards meaningful, lifesaving treatments.

We have sites all over Australia and New Zealand, so jump onto https://www.trialnet.org/participate and get started today.

Our nurses can't wait to meet you! 👩‍⚕️💙

29/08/2018

Participant Spotlight! ✨

We are so proud of Annie and Lucie! They've just had their very first TrialNet blood tests in Melbourne. How good is that? And they had loads of fun at the Walter and Eliza Hall Institute!

These girls are helping accelerate our Type 1 Diabetes research and we can't thank them enough. If you have a family member with Type 1, TrialNet can help you understand your own risk while working towards meaningful, lifesaving treatments.

We have sites all over Australia and New Zealand, so jump onto https://www.trialnet.org/participate and get started today.

Our nurses can't wait to meet you! 👩‍⚕️💙

28/03/2018

Australian TrialNet Investigator and T1D research extraordinaire Professor Peter Colman will be delivering a public lecture at the Royal Melbourne Hospital on Wednesday the 30th of May at 12pm. All welcome!

Help us spread the word and 'share' away!

Please register for your free ticket here
https://www.eventbrite.com.au/e/prevention-is-the-cure-clinical-research-advances-in-diabetes-tickets-44242983956

Free Lecture - Professor Peter Colman will explore the ground-breaking research being done to prevent Type 1 Diabetes by recognising the symptoms earlier. Professor Colman will also talk about pioneering treatments, including the revolutionary closed-loop insulin pump for Type 1 Diabetes. With over....

14/03/2018

Rose is 25 years old and recently completed her TrialNet Pathway to Prevention Monitoring visit at the Royal Melbourne Hospital. Rose was eligible for type 1 diabetes risk screening through TrialNet because her sister, Emily was diagnosed with type 1 diabetes at age 14. In this video Rose and Emily chat about their experience in TrialNet.

Are you interested in finding out your/your family's risk of developing type 1 diabetes?

You may be eligible to participate at no cost if you:

• are between the ages of 1 and 45 and have a parent, brother/sister, or child with T1D (ages 1-45)
• are between the ages of 1 and 20 and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D.

Visit https://www.diabetestrialnet.org/webapp/PreRegTracking/OnlineScreening.aspx to register your interest today!
JDRF Australia Diabetes Victoria Diabetes Australia Type 1 Diabetes TrialNet Diabetes WA Diabetes Queensland Diabetes NSW & ACT Diabetes Tasmania

22/11/2017

A big thankyou also to the participants around Australia and New Zealand for their participation in the TrialNet oral insulin study, results are out!

The risk for type 1 diabetes development was not decreased in autoantibody-positive relatives of patients with type 1 diabetes randomly assigned to oral insulin, and oral insulin did not delay the time to diabetes progression, study data show. “We now know that we can identify people long befo...

21/08/2017

Dr. Carla Greenbaum, TrialNet Chair, from the Benaroya Research Institute in Seattle, Washington, USA, will be speaking at the upcoming ADS & ADEA meeting in Perth, Australia on Wednesday August 30th, 2017. Her talk titled “Disease modifying therapy in type 1 diabetes; what an endocrinologist needs to know” will highlight TrialNet’s recent research advances and how TrialNet is aiming to stop disease progression in people identified at the early stages of type 1 diabetes.

She will be joining other national and international experts to promote the exchange of the latest clinical practices and cutting edge research in diabetes.

For more information about the ADS & ADEA meeting, visit http://www.ads-adea.org.au

we can now identify individuals at very early stages of T1D. This alone can prevent dka. But the real issue is to delay progession to clinical disease. Recent trial results are tantalizing.